Nagi Bioscience raises seed financing round

The EPFL spin-off today announced the closing of a seed round for the first worm-on-chip technology for drug / chemical screening.

This year’s Headstart finalist Nagi Bioscience announced today the closing of a CHF 1.8 million seed financing round, led by the leading Swiss venture capital platform Investiere, with participation from Zürcher Kantonalbank, NEST pension fund and private investors from Switzerland and United States.

Nagi Bioscience, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), was founded in January 2019 and originates from a 5-year long scientific collaboration between the two company founders, Matteo and Laurent, and from a real need in EPFL life-science laboratories: automate  C. elegans  research and testing.

The startup has developed an innovative “Organism-on-Chip” technology, first all-in-one device for fully automated high-content screening of drugs / cosmetics / chemicals on micro-worms, within disposable microfluidic chips. Their goal is to revolutionize the way toxic and beneficial effects of substances are tested today, by bringing a significant reduction of costs and delays of pharmaceutical and chemical research.

The new capital will be used for further development of the rapid toxicology testing device and its market access.